MI Cancer Seek
Caris Life Sciences · Decision date Oct 16, 2026
What did the FDA approve?
The FDA record P240010/S007, dated 2026-10-16, is an approved PMA supplement for MI Cancer Seek (MCS). Its stated purpose is migration of the MCS Bioinformatics Pipeline from an on-premises High-Performance Computing (HPC) cluster to Amazon Web Services (AWS) cloud infrastructure. The supplement type is Real-Time Process, with reason Change Design/Components/Specifications/Material.
The device category is a next generation sequencing oncology panel, somatic or germline variant detection system, under product code PQP and specialty Medical Genetics; applicant Caris Life Sciences. The identifier places S007 under the original P240010, so this is a supplement to that PMA, not a new approval of the whole system. The record does not give computing specifications, validation data, or findings on safety or clinical effectiveness; the migration description is the sponsor's stated purpose, not proof of those outcomes.
FDA approval order statement
Approval for migration of the MI Cancer Seek (MCS) Bioinformatics Pipeline from an on-premises High-Performance Computing (HPC) cluster to Amazon Web Services (AWS) cloud infrastructure
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Medical Genetics
- Decision date
- Oct 16, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240010/S007
- Regulatory pathway
- PMA supplement
- Applicant
- Caris Life Sciences
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Caris Life Sciences
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240010. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240010 · Original PMA
MI Cancer Seek
P240010/S007 received
Application receipt date recorded by FDA.
P240010/S007 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P240010. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240010
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MI Cancer SeekP240010 | Caris Life Sciences | PMA approval | Nov 5, 2024 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Caris Life Sciences
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4610 S. 44th Pl., Phoenix, AZ, 85040
Sources and methodology
- Original FDA record: P240010/S007
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


